Literature DB >> 29345291

MicroRNA-1271 functions as a metastasis and epithelial-mesenchymal transition inhibitor in human HCC by targeting the PTP4A1/c-Src axis.

Chao Li1, Yezhen Jiang1, Runchen Miao1, Kai Qu1, Jingyao Zhang1, Chang Liu1.   

Abstract

MicroRNAs (miRNAs or miRs) have been shown to regulate hepatocellular carcinoma (HCC) metastasis. In the present study, we focused on the functions of miR-1271 in HCC metastasis. The downregulation of miR-1271 was found to be associated with to venous infiltration, an advanced TNM stage (III+IV stage) and a shorter survival time. Our in vitro and in vivo data demonstrated that miR-1271 prevented HCC cell migration and invasion, as well as the formation of lung metastatic clusters. In addition, miR-1271 was demonstrated to markedly inhibit the epithelial-mesenchymal transition (EMT) of HCC cells. Importantly, protein tyrosine phosphatase type IVA member 1 (PTP4A1) was identified as a direct downstream target of miR-1271 in HCC. Furthermore, we confirmed that the phosphorylation of c-Src at Tyr416 mediated by PTP4A1 was a potential anti-HCC mechanism of action of miR-1271. On the whole, our data indicate that miR-1271 inhibits HCC metastasis by targeting the PTP4A1/c-Src signaling pathway and may serve as a prospective cancer therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29345291     DOI: 10.3892/ijo.2017.4224

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  14 in total

Review 1.  MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.

Authors:  Ulrich H Weidle; Daniela Schmid; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069

2.  Long non-coding RNA USP30-AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA-299-3p and thereby overexpressing PTP4A1.

Authors:  Mengyue Chen; Yugang Chi; Hongwei Chen; Limei Zhao
Journal:  Oncol Lett       Date:  2021-04-29       Impact factor: 2.967

3.  Serum starvation induces cell death in NSCLC via miR-224.

Authors:  Guoqin Wang; Jiangqiong Han; Li Zhuang; Shijuan Li; Quan Gong; Yunlan Chen
Journal:  Onco Targets Ther       Date:  2019-05-22       Impact factor: 4.147

4.  microRNA-16 Via Twist1 Inhibits EMT Induced by PM2.5 Exposure in Human Hepatocellular Carcinoma.

Authors:  Hao Zhang; Zhihu Li
Journal:  Open Med (Wars)       Date:  2019-09-15

5.  miR-1271 inhibits growth, invasion and epithelial-mesenchymal transition by targeting ZEB1 in ovarian cancer cells.

Authors:  Yanni Jiao; Guiping Zhu; Jiang Yu; Ying Li; Man Wu; Jing Zhao; Xiangwen Tian
Journal:  Onco Targets Ther       Date:  2019-08-28       Impact factor: 4.147

6.  OIP5-AS1 contributes to tumorigenesis in hepatocellular carcinoma by miR-300/YY1-activated WNT pathway.

Authors:  Yu Wang; Lei Dou; Yun Qin; Huiyuan Yang; Peng Yan
Journal:  Cancer Cell Int       Date:  2020-09-09       Impact factor: 5.722

7.  Long non‑coding RNA MEG3 inhibits cell migration and invasion of non‑small cell lung cancer cells by regulating the miR‑21‑5p/PTEN axis.

Authors:  Dongjin Lv; Qing Bi; Yunxia Li; Jie Deng; Na Wu; Shu Hao; Mingli Zhao
Journal:  Mol Med Rep       Date:  2021-01-26       Impact factor: 2.952

8.  Huaier Extract Attenuates Acute Kidney Injury to Chronic Kidney Disease Transition by Inhibiting Endoplasmic Reticulum Stress and Apoptosis via miR-1271 Upregulation.

Authors:  Jing-Ying Zhao; Yu-Bin Wu
Journal:  Biomed Res Int       Date:  2020-12-10       Impact factor: 3.411

9.  Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2.

Authors:  Gang Fan; Jin Jiao; Feng Shen; Fulu Chu
Journal:  Thorac Cancer       Date:  2020-06-08       Impact factor: 3.500

10.  MicroRNA-552 promotes hepatocellular carcinoma progression by downregulating WIF1.

Authors:  Chao Li; Zi Wang; Shuangjiang Chen; Jingyao Zhang; Kai Qu; Chang Liu
Journal:  Int J Mol Med       Date:  2018-09-17       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.